NEW YORK (GenomeWeb News) – Genetic Technologies said today that it has reached a settlement and license agreement with Eurofins STA Laboratories in an infringement lawsuit over Genetic Technologies' non-coding DNA technology.
Genetic Technologies did not disclose financial terms of the agreement, which gives Eurofins non-exclusive rights to a number of its patents.
The Australian company filed the suit against Eurofins and nine other firms in the US District Court for the District of Colorado in May 2011.
The other defendants in the GTG suit include Agilent Technologies; Bristol-Myers Squibb; GlaxoSmithKline; Hologic; Merial; Navigenics; Neogen; Pfizer; and 454 Life Sciences.
Earlier in 2011, Genetic Technologies concluded a lawsuit against a number of companies over the same patent, including Gen-Probe, Beckman Coulter, and Orchid Cellmark,
The company also has a similar suit against American Esoteric Laboratories; Clinical Pathology Laboratories Southeast; Clinical Pathology Laboratories; East Side Clinical Laboratory; Fairfax Medical Laboratories; Pathology Laboratories; and Sonic Healthcare USA.
Genetic Technologies said that Eurofins is the third counterparty in this case to settle, and that ongoing discussions with other counterparties are currently progressing.